{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Objective response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Progressive Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Not evaluable"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Objective response rate per The International Working Group response criteria (1999): Complete Response (CR), disappearance of all disease sustained for at least four weeks; Partial Response (PR), \\>=50% decrease in the sum of the products of of the greatest perpendicular diameters of all measurable lesions, sustained for at least four weeks. Stable Disease (SD), \\< 50% change in the sum of the products of of the greatest perpendicular diameters of all measurable lesions, sustained for at least twelve weeks.","groups":[{"description":"Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.\n\nAntineoplaston therapy (Atengenal + Astugenal): Patients with Multiple Myeloma will receive Antineoplaston therapy (Atengenal + Astugenal).\n\nThe daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.","id":"OG000","title":"Antineoplaston Therapy"}],"paramType":"NUMBER","populationDescription":"All patients enrolled in the study.","reportingStatus":"POSTED","timeFrame":"36 months","title":"Number of Participants With Objective Response, Stable Disease, Progressive Disease or Not Evaluable","type":"PRIMARY","unitOfMeasure":"participants"}